Found 84 articles
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
Femasys Inc. (NASDAQ: FEMY) today highlighted that its FemaSeed intratubal insemination product, a revolutionary approach to enhancing fertilization, is expected to serve as a first-line therapeutic option that is substantially lower cost with significantly less risk than assisted reproductive methods, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
Femasys Inc. today announced the appointment of Richard Spector to chief commercial officer (CCO), effective February 2024.
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
Femasys Inc. today announced that it has activated enrollment for its pivotal FemBloc® trial at University of California, Davis (“UC Davis”) Medical Center in Sacramento, California.
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
Femasys Inc. today announced that it has activated enrollment for its pivotal FemBloc trial at another academic site, University of Utah Hospital in Salt Lake City, Utah.
Femasys Inc. (NASDAQ: FEMY) today announced that it has activated enrollment for its pivotal FemBloc® trial at Stanford Medicine (“Stanford”) in Palo Alto, California.
Femasys Inc. today announced the appointment of James Liu, M.D., as Chief Medical Officer.
Femasys Inc. today announced completion of enrollment in the LOCAL FemaSeed® pivotal clinical trial, designed to evaluate women undergoing FemaSeed cycles due to male factor infertility.
PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedical company focused on meeting significant unmet needs for women worldwide.
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
Femasys Inc. today announced a strategic upfront investment of $6.85 million by public biotech company, PharmaCyte Biotech, Inc. (Nasdaq: PMCB) and other healthcare investors.
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
Femasys Inc. today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.
Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons
Femasys Inc. today announced that it will highlight its product candidate in late stage clinical development, FemBloc ® , as well as showcase three of its marketed products advancing women’s health FemVue®, FemCath® and FemCerv®, at the annual meeting of the American Association of Gynecologic Laparoscopic Surgeons (AAGL) being held in Nashville, Tennessee from November 5-8, 2023.
Femasys Inc. announced that it has it has received notice from The Nasdaq Stock Market LLC informing Femasys that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550 for continued listing on The Nasdaq Capital Market.
Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine
Femasys Inc. today announced that it will be exhibiting at the annual meeting of the American Society of Reproductive Medicine (ASRM): “The Past, The Present, and The Pipeline”, being held in New Orleans.
Femasys Inc. today announced that it has successfully completed the annual Medical Device Single Audit Program (MDSAP) surveillance audit with no nonconformances and no findings.
Femasys Inc. today announced that it has activated enrollment for its pivotal FemBloc trial at its first academic site located in Brooklyn, New York.
Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution
Femasys Inc. (NASDAQ: FEMY) today announced it has received 510(k) Clearance from the United States Food and Drug Administration (FDA) for FemaSeed®, an innovative infertility treatment designed to deliver sperm directly to where conception occurs in a woman’s fallopian tube.
Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control
Femasys Inc. today announced the achievement of First-Patient-In for its pivotal clinical trial evaluating FemBloc ® , a first-of-its-kind, non-surgical, non-implant, in-office solution for permanent birth control for women.
Femasys Inc. today announced that Kathy Lee-Sepsick, founder, president & chief executive officer, will virtually present and also participate in one-on-one investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.
Femasys Inc. announced that it has obtained a Medical Device Establishment License from Health Canada.
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update
Femasys Inc. announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.